Pages that link to "Q48275051"
Jump to navigation
Jump to search
The following pages link to SLN approach for nose-to-brain delivery of alprazolam (Q48275051):
Displaying 6 items.
- Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease (Q26783306) (← links)
- Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research (Q38117056) (← links)
- Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation (Q42005180) (← links)
- Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting. (Q52654049) (← links)
- Enhancement of brain-targeting delivery of danshensu in rat through conjugation with pyrazine moiety to form danshensu-pyrazine ester. (Q52663389) (← links)
- Physico-chemical characterisation, cytotoxic activity, and biocompatibility studies of tamoxifen-loaded solid lipid nanoparticles prepared via a temperature-modulated solidification method. (Q53086364) (← links)